Skip to content

Search

Measuring delivery and impact in community-based health promotion initiatives: development and overview of the Healthway Evaluation Framework

Robust evaluation is critical for understanding and enhancing the impact of health promotion initiatives. However, many community-based organisations face challenges in planning and conducting evaluation due to limitations in knowledge, resources, and the applicability of existing evaluation frameworks. The Healthway Evaluation Framework, and its accompanying practical Measurement Toolkit, was designed to support evaluation planning, implementation, and reporting across diverse health promotion programs and settings.

Respiratory Syncytial Virus Transmission in Closed Community Settings That Include Children: A Systematic Review and Meta-Analysis

Respiratory syncytial virus (RSV) is a leading cause of severe respiratory infections in children and is predominantly acquired and spread in community settings such as households and early childhood education centres. This review aims to synthesise the available evidence on RSV transmission in closed community settings that include children, with a focus on secondary attack rates.

A randomized prospective study of neonatal hepatitis B vaccine immunogenicity in The Gambia and Papua New Guinea

Protection of newborns from infection can be achieved through maternal or vaccine-induced antibodies, but the factors influencing vaccine protection (correlate of protection) and subsequent infant immunity remain insufficiently understood. Further investigation is essential to optimize early-life vaccination strategies.

Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Enteric infectious diseases claim more than 1 million lives annually and are among the top ten causes of death in children younger than 5 years. Remarkable global investment has been dedicated to enteric infectious disease prevention and control; however, the shifting global health landscape is testing the continuance of progress.

Implementation of Evidence-Based, Person-Centered Alternative Delivery Models for Cardiac Rehabilitation in a Rural and Remote Population: The Country Heart Attack Prevention (CHAP) Project

Access and adherence to cardiac rehabilitation (CR) remain suboptimal, particularly in rural and remote settings. This study evaluated the implementation of person-centred, evidence-based CR delivery model tailored to improve access and completion.

Corrigendum to: “COVID-19 monitoring with sparse sampling of sewered and non-sewered wastewater in urban and rural communities” [iScience, Volume 26, Issue 7 (2023) 107019]

Anthony Kicic BSc (Hons) PhD Head, Airway Epithelial Research; WA Cystic Fibrosis Research Collaborative Program Fellowship; Stan Perron Charitable

The Complex and Multifaceted Nature of Social Media: Perspectives From Young Adolescents, Parents and Experts

This study explores the complex and multifaceted nature of social media use among young adolescents, drawing on the perspectives of young adolescents, parents and experts. It examines both the benefits and risks of social media and associated implications for adolescent mental health, self-development and social relationships.

First global synthesis of heat-related mental health impacts in children and young people: a systematic review and meta-analysis

Climate change is increasing the frequency and severity of non-optimal temperatures and heatwaves, posing risks to public health, especially for children and young people. We performed a systematic review and meta-analysis to assess the impacts of (i) non-optimal ambient temperatures and (ii) heatwaves on mental health outcomes in this group globally.

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study

Elexacaftor/tezacaftor/ivacaftor(ELX/TEZ/IVA) was safe and efficacious in children with CF 2-5y with at least one F508del allele in 24-week phase 3 Trial 445-111. Children who completed 445-111 were eligible for the long-term safety and efficacy extension trial.